Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]hED1
- Development stage
- Preclinical
- Lead developer
- Indiana University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
[18F]hED1 is a fluorine-18 labeled homoglutamic acid derivative designed as a novel positron emission tomography (PET) imaging radiotracer targeting the cystine/glutamate antiporter (System Xc–). System Xc– is an amino acid transport system that is upregulated in glioblastoma and associated with increased treatment resistance. Developed by researchers at the University of Wisconsin-Madison, UiT The Arctic University of Norway, and Indiana University School of Medicine, [18F]hED1 has demonstrated clear radiotracer accumulation within tumor tissue and renal clearance in preclinical glioblastoma models. The adaptable radiolabeling chemistry of the homoglutamic acid derivative also suggests compatibility with therapeutic radionuclides (such as iodine-131 or astatine-211), highlighting its potential as a theranostic agent.
- Other names
- 18F-hED118F-labeled homoglutamic acid derivative[18F]F-hED1hED1hED-1hED 1
02
Targets
SLC7A11 (Cystine-Glutamate Antiporter)
Beyond the preview
Go deeper on [18F]hED1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]hED1.